Ignite Creation Date:
2025-12-24 @ 9:45 PM
Ignite Modification Date:
2026-02-05 @ 5:33 AM
Study NCT ID:
NCT03219632
Status:
COMPLETED
Last Update Posted:
2017-07-17
First Post:
2017-07-12
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECG
Sponsor:
Seoul National University Bundang Hospital
Organization:
Study Overview
Official Title:
Angiotensin Blocking Effect of Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECG: a Prospective, Multicenter, Observational Registry
Status:
COMPLETED
Status Verified Date:
2017-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Assess the efficacy of fimasartan on left ventricular hypertrophy in hypertensive patients
Detailed Description:
Patients who were diagnosed with left ventricular hypertrophy (LVH) by ECG at the start of the study are followed up at 3-month intervals for 1 year.
Increase Fimasartan if blood pressure is not controlled.
Increase Fimasartan if blood pressure is not controlled.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: